Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHL

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

Updates from the ECHELON-1 studyПодробнее

Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHLПодробнее

Overview of ECHELON-1 Study for Hodgkin LymphomaПодробнее

Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 cla...Подробнее

A new day with ECHELON-1Подробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

Updated ECHELON-1 Findings Demonstrate Toxicities of Brentuximab Vedotin Combo in Hodgkin LymphomaПодробнее

Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin LymphomaПодробнее

ECHELON-1 Trial: Significance in Hodgkin LymphomaПодробнее

Impact of ECHELON-1 on the future of treatmentПодробнее

The Impact of Brentuximab Vedotin as PTCL TreatmentПодробнее

Patient Selection Based on the ECHELON-1 Study in cHLПодробнее

A 10-year PFS simulation model based on the ECHELON-1 trial in Hodgkin lymphomaПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 studyПодробнее

ECHELON-1 trial data from ASH 2017: controversies and clinical translationПодробнее

Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphomaПодробнее